NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

TDOC

Teladoc Health Inc. New York Stock Exchange
$233.86
Open: $257.02 High: $264 Low: $233.45 Close: $234.597
Range: 2021-02-24 - 2021-02-25
Volume: 6,015,134
Market: Open
Powered by Finage Stock APIDelayed data
TDOC
Teladoc Health Inc. 2 Manhattanville Road Purchase NY, 10577 http://www.teladoc.com
Teladoc Inc provides telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone.
  • CEO: Jason N. Gorevic
  • Employees: 2,032
  • Sector: Technology
  • Industry: Application Software
TDOC News
Latest news about the TDOC
  • Teladoc Stock Falls on Downbeat Forecast for Membership

    CEO Jason Gorevic said the virtual healthcare provider has to 'refill the pipeline' after rapid membership growth in 2020.

    View More →
  • Stocks Today Fall But Moderna Surges Off Key Level; This Pot Stock Tanks 12%, Teladoc Drops

    Moderna, a leader in messenger RNA technology, recently failed to break out of a new base. But it's now getting solid buying support at the critical 50-day moving average.

    View More →
  • HealthTech Trends 2021: CEO’s of Teladoc, Reliq Health, Relay Medical and Veeva Systems, Driving Revenue Growth with Innovation and New Markets Expansions

    NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Teladoc Health (NYSE: TDOC), Reliq Health Technologies (OTC:RQHTF) (TSX.V:RHT), Relay Medical (CSE: RELA) (OTC: RYMDF) and Veeva Systems (NYSE: VEEV). The US healthcare market is estimated at $2.8 trillion - and the largest in the world. Fast moving innovators are now driving a transformation wave - and creating new opportunities for investors. Wall Street Reporter highlights the latest comments from industry thought leaders: Reliq Health Technologies (OTC:RQHTF) (TSX.V:RHT) CEO Lisa Crossley: “2021 is Breakout Year for Our Telehealth Platform - On Path To $100 Million Revenues” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Reliq Health Technologies (OTC:RQHTF) CEO, Lisa Crossley explained how the company’s iUGO telehealth remote patient monitoring platform is positioned for explosive revenue growth starting in 2021. Reliq’s powerful iUGO telemedicine platform supports care coordination and community-based virtual healthcare, allows complex patients to receive high quality care at home, improving health outcomes, and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. In her presentation, Lisa outlines RQHTF’s growth strategy, and path to $100 million revenues by 2024 (which could give RQHTF a valuation of $1 billion+ based on current peer group valuations). RQHTF is now at an inflection point - with three significant new contracts announced, just in the past 30 days. Watch Reliq Health Tech (OTC:RQHTF) (TSX.V:RHT) NEXT SUPER STOCK Video: http://bit.ly/3qYX5ZK Teladoc Health (NYSE: TDOC) CEO Jason Gorevic: “Virtual Care Trend is Only Accelerating - and Here to Stay (Beyond Pandemic)” “...We continue to see strong evidence of sustained utilization increases for virtual care... One clear driver of this strength has been a steady and broad-based acceleration in our noninfectious disease-related visits. Visits for conditions such as hypertension, back pain, anxiety and depression represent over half of our general medical visit volume, up from approximately 1/3 a year ago, as our comprehensive portfolio of services enables us to meet the increasing consumer demand for virtual care.” “...Momentum in specialty visit growth, combined with the broadening diversity of diagnoses and robust overall registration growth, continues to give us a high degree of confidence in the sustainability of our volume growth. It also reinforces our strategy of consistently expanding the clinical scope of our services, which will take a quantum leap forward when we incorporate the Livongo capabilities focused on helping people who live with chronic conditions.” Teladoc Health (NYSE: TDOC) Earnings Highlights: https://bit.ly/3fg9jIt Relay Medical (CSE: RELA) (OTC: RYMDF) President Clark Kent: “AI Diagnositics Targeting Billion Dollar Healthcare Opportunities” In a recent presentation at Wall Street Reporter’s Investors Discovery Day livestream, Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) President Clark Kent, discussed the company’s diagnostics and AI HealthTech focus, which targets multi-billion dollar opportunities in global healthcare markets. A highlight of the presentation was a video demo of the company’s rapid testing and tracking platform for infectious diseases, including COVID-19. The platform has already been successfully deployed in testing and tracking infectious disease outbreaks globally, including ebola and malaria. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn February 24 - Relay Medical and and Fio Corporation - together Fionet Rapid Response Group announced that the Greater Toronto Airports Authority (GTAA) has engaged FRR to deploy the Fionet Platform for on-site COVID-19 rapid testing and real-time reporting at Toronto - Lester B. Pearson International Airport ("Toronto Pearson"). The testing program is set to commence March 1, 2021 in support of multiple research studies supported in part by funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Under the terms of the engagement, starting March 1, 2021 the Fionet digital workflow, testing, and data infrastructure will be deployed at Toronto Pearson to help manage COVID-19 testing for both passengers and employees. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn Veeva Systems Inc. (NYSE: VEEV), CEO Peter Gassner: “Veeva’s Cloud Innovation Powering Pharma & LifeSciences”“...We are expanding customer relationships during a major digital transformation...helping customers with immediate needs to open up digital channels in commercial and clinical, and we're also helping them to find the right digital models for the long-term…For example, on the commercial side, we recently announced the strategic partnership with an emerging biopharma to help them define and execute an innovative digital-first commercial model. They will utilize the full commercial cloud, including Veeva CRM, Data Cloud, Veeva Link, MyVeeva, and Business Consulting. That level of trust and confidence in our ability to deliver came through strongly in our Q3 new wins and expansions. “..We added 19 new CRM customers, our biggest quarterly increase yet. We continue to grow market share and had multiple international expansions in CRM with existing customers...We also progressed well in our newer areas, including Data Cloud, MyVeeva for Doctors, and Veeva Link. We expect these products will set us up for a long runway of growth in commercial. It's an exciting time in commercial and a time of change. We think our customers can generate meaningful productivity gains over the coming years as they increasingly leverage digital..” Veeva Systems (NYSE: VEEV) Earnings Call Highlights Available at: http://bit.ly/3dKZxiF WALL STREET REPORTER Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K About Wall Street Reporter’s Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/ CONTACT: WALL STREET REPORTER (212) 871-2057 ext 7 www.WallStreetReporter.com

    View More →
  • Dow Jones Futures: Tech Stocks Fall As GameStop Skyrockets, Tesla Model 3 Production Halted; Nvidia Leads Five Earnings Movers

    Nasdaq futures are under pressure again before the open. Tesla Model 3 output halted. GME stock is soaring. Nvidia leads key earnings movers.

    View More →
  • Teladoc Losses Widen In 4Q; Shares Drop 6% After-Hours

    Teladoc Health’s shares dropped 6.1% in extended-hours trading on Feb. 24 as the virtual healthcare provider’s 4Q net loss per share widened to $3.07 from a net loss per share of $0.26 in 4Q FY19. Analysts were expecting a loss of $0.24 per share. Revenue for the quarter increased 145% year-on-year to $383.3 million, ahead of consensus estimates of $378.93 million. Teladoc Health’s (TDOC) CEO, Jason Gorevic said, “As virtual care shifted to become a consumer expectation in 2020, Teladoc Health not only met the rapidly growing demand, but we transformed our company to define a new category of whole-person virtual care. By accelerating our mission to transform the health care experience, we exceeded our fourth-quarter and full-year 2020 expectations and see strong momentum across our global business in 2021 as the market embraces the breadth and depth of our unique capabilities.” In the fourth quarter, the jump in revenues for TDOC was driven by a 188% year-on-year rise in access fees revenues in the United States and an 82% year-on-year increase in revenues earned from visit fees in the US. For 1Q FY21, TDOC expects revenues to be in the range of $445 million to $455 million and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to be between $45 million and $48 million. For FY21, the company has forecasted revenues to range between $1.95 billion and $2 billion and adjusted EBITDA of between $255 million and $275 million. (See Teladoc Health stock analysis on TipRanks) On Feb. 22, Jefferies analyst David Windley raised his price target to $264 from $205 and reiterated a Hold on the stock. Windley believes that there is an industry shift towards “true longitudinal virtual care” and TDOC is well-equipped to serve this need with a range of solutions and channel partners. Windley said, “We estimate Adj. EBITDA margins to expand 230bps in FY21 (vs. mgt’s LT [long-term] target of 200-300bps/yr), and don’t think top line guidance will disappoint.” “That said, utilization is a wild card this year, and Paid Membership is always difficult to handicap (though mgt’s bookings and pipeline commentary has been bullish). We expect BH [behavioural healthcare] growth to offset much slower growth in paid visits, which we estimate +3% YoY (which assumes +10.7M gross Paid Members),” Windley added. The rest of the Street is cautiously optimistic on the stock with a Moderate Buy consensus rating based on 6 Buys and 9 Holds. The average analyst price target of $245.31 implies downside potential of around 4% to current levels. Related News: Fisker Inks MOU With Foxconn To Develop EV; Shares Pop 22% Pre-Market Nvidia Posts Better-Than-Expected 4Q Earnings; Street Remains Bullish Five9 4Q Pops 10% Pre-Market On Blowout Quarter More recent articles from Smarter Analyst: Nvidia Posts Better-Than-Expected 4Q Earnings; Street Remains Bullish PRA Health Sciences To Be Acquired By ICON For $12B; Shares Pop 19% Sage Posts Surprise Quarterly Profit As Sales Surge; Shares Pop 6% Six Flags Reports Worse-Than-Feared Quarterly Loss On Weak Attendance

    View More →
  • 3 Top Healthcare Stocks to Buy in 2021

    Moderna, Teladoc Health, and Fulgent Genetics have all spiked a lot higher because of COVID-19. And all three companies have platforms for growth over the next decade.

    View More →
  • 3 Growth Stocks You'll Want to Buy in the Next Market Crash

    What's an 11-letter word that describes a stock market crash? Major market downturns present opportunities for investors who have a long-term perspective to buy fantastic stocks at a discount. Fiverr (NYSE: FVRR) provides a platform that connects freelancers with buyers of digital services.

    View More →
  • Premarket Movers Thursday - GameStop, AMC, Moderna, Plug Power

    Stocks moving in premarket trading on Thursday include GameStop, Moderna, Wayfair, Best Buy and Teladoc Health.

    View More →
  • Teladoc Health (TDOC) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Teladoc Health fourth-quarter 2020 conference call. On this call to discuss the results are Jason Gorevic, our chief executive officer, and Mala Murthy, our chief financial officer. Please note that we will be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc health's performance.

    View More →
  • Recap: Teladoc Health Q4 Earnings

    Shares of Teladoc Health (NYSE:TDOC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 3.85% over the past year to ($0.27), which missed the estimate of ($0.24). Revenue of $383,321,000 up by 144.95% year over year, which beat the estimate of $378,410,000. Guidance Teladoc Sees Q1 Sales $445M-$455M vs $446.01M Est., Sees FY21 Sales $1.95B-$2.0B vs $1.95B Est. Details Of The Call Date: Feb 24, 2021 Time: 04:30 PM View more earnings on TDOC ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.teladochealth.com%2F&eventid=2947861&sessionid=1&key=E2A4D04F5718E8A365E482A3CF13963F&regTag=&V2=false&sourcepage=register Recent Stock Performance 52-week high: $308.00 52-week low: $102.01 Price action over last quarter: Up 14.74% See also: Best Private Health Insurance Company Description Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the Internet, video, and phone. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated on a subscription basis (per member per month); the balance comes from visit fees. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members; most recently, the company has also started to market directly to consumers while expanding its service portfolio. The cornerstone of Teladoc's business is to provide healthcare access to members in real time to avoid excessive health plan costs. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 24, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Teladoc shares tumble 7% on Q4 results

    Teladoc Health Inc.'s shares were initially down 7% in extended trading Wednesday after the virtual healthcare company reported fiscal fourth-quarter results. Teladoc reported an adjusted net loss of $394 million, or $3.07 a share, compared with a net loss of $19 million, or 26 cents a share, in the year-ago quarter. Revenue jumped 145% to $383.3 million from $156.5 million a year ago. Analysts surveyed by FactSet had expected a loss of 26 cents a share on revenue of $379 million. Teladoc's stock has climbed 116% over the last 12 months. The broader S&P 500 index has improved 26% in the last year.

    View More →
  • Top Healthcare Stocks for March 2021

    These are the healthcare stocks with the best value, fastest growth, and most momentum for March 2021.

    View More →
  • Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results

    Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million Full year revenue grows 98% year-over-year to $1,094.0 million and total visits increase 156% to 10.6 million Issues 2021 first-quarter and full-year guidance PURCHASE, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported strong financial results for the fourth quarter and full year ended December 31, 2020. “As virtual care shifted to become a consumer expectation in 2020, Teladoc Health not only met the rapidly growing demand, but we transformed our company to define a new category of whole-person virtual care,” said Jason Gorevic, chief executive officer of Teladoc Health. “By accelerating our mission to transform the health care experience, we exceeded our fourth-quarter and full-year 2020 expectations and see strong momentum across our global business in 2021 as the market embraces the breadth and depth of our unique capabilities.” Financial Highlights for the Fourth Quarter and Full Year Ended December 31, 2020 Revenue ($ thousands, unaudited) Quarter Ended Year over Year Year Ended Year over Year December 31, Growth December 31, Growth 2020 2019 2020 2019 Access Fees Revenue U.S. $282,826 $98,052 188 % $737,408 $356,656 107 % International 33,131 28,924 15 % 124,392 106,640 17 % Total 315,957 126,976 149 % 861,800 463,296 86 % Visit Fee Revenue U.S. 53,149 29,222 82 % 206,093 88,669 132 % International 113 291 (61)% 818 1,342 (39)% Total 53,262 29,513 80 % 206,911 90,011 130 % Other U.S. 13,589 0 N/M 23,888 0 N/M International 513 0 N/M 1,363 0 N/M Total 14,102 0 N/M 25,251 0 N/M Total Revenue $383,321 $156,489 145 % $1,093,962 $553,307 98 % N/M – Not meaningful Membership and Visit Fee Only Access (millions) December 31, Growth 2020 2019 U.S. Paid Membership 51.8 36.7 41% U.S. Visit Fee Only Access 21.3 19.3 10% Chronic Care Enrollment 0.6 — N/M Visits (thousands) Quarter Ended Year over Year Year Ended Year over Year December 31, Growth December 31, Growth 2020 2019 2020 2019 U.S. Visits 2,515 975 158% 8,820 3,104 184% International Visits 440 264 67% 1,771 1,034 71% Total Visits 2,955 1,239 139% 10,591 4,138 156% Utilization 17.7% 9.5% 826pt 16.0% 9.3% 664pt Platform-Enabled Sessions* 1,089 — N/M 2,076 — N/M Total Visits & Sessions Provided & Enabled 4,044 1,239 226% 12,667 4,138 206% * Platform-Enabled Session is a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our client’s patient, or between care providers. We believe platform-enabled sessions are an indicator of the value our clients derive from the platform they license from us in order to facilitate virtual care. Net loss was $(394.0) million for the fourth quarter 2020 compared to $(19.0) million for the fourth quarter 2019. Net loss was $(485.1) million for the full year 2020 compared to $(98.9) million for the full year 2019. The fourth quarter and full year 2020 includes $57.6 million and $88.2 million, respectively, of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. Net loss for the fourth quarter and full year 2020 also includes $54.7 million of stock-based compensation related to Livongo stock awards that continue to vest after the merger. Net loss also includes an income tax benefit of $85.5 million for the fourth quarter 2020 and $90.9 million for the full year 2020.Net loss per basic and diluted share was $(3.07) for the fourth quarter 2020 compared to $(0.26) for the fourth quarter 2019. Net loss per basic and diluted share was $(5.36) for the full year 2020 compared to $(1.38) for the full year 2019. The fourth quarter and full year 2020 includes $0.45 and $0.97 per share, respectively, of acquisition and integration related costs as well as $2.59 and $3.66 per share, respectively, of accelerated stock-based awards expense related to the merger with Livongo. Net loss per basic and diluted share for the fourth quarter and full year 2020 also includes $0.43 and $0.60 per share, respectively, of stock-based compensation related to Livongo stock awards that continue to vest after the merger. Net loss per basic and diluted share for the fourth quarter and full year 2020 also includes an income tax benefit of $0.67 and $1.00 per share, respectively.GAAP Gross margin, which includes depreciation and amortization, was 67.2 percent for the fourth quarter 2020 and 63.8 percent for the fourth quarter 2019. GAAP Gross margin which includes depreciation and amortization, was 63.1 percent for the full year 2020 and 65.8 percent for the full year 2019.Adjusted Gross margin was 67.9 percent for the fourth quarter 2020 compared to 64.6 percent for the fourth quarter 2019. Adjusted Gross margin was 64.3 percent for the full year 2020 compared to 66.7 percent for the full year 2019.EBITDA was a loss of $(421.5) million for the fourth quarter 2020 compared to a loss of $(5.7) million for the fourth quarter 2019. EBITDA for the fourth quarter 2020 includes $57.6 million of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. EBITDA was a loss of $(436.9) million for the full year 2020 compared to a loss of $(41.5) million for the full year 2019. EBITDA for the full year 2020 includes $88.2 million of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. EBITDA for the fourth quarter and full year 2020 also includes $54.7 million of stock-based compensation related to Livongo stock awards that continue to vest after the merger.Adjusted EBITDA was $50.4 million for the fourth quarter 2020 compared to $15.2 million for the fourth quarter 2019. Adjusted EBITDA was $126.8 million for the full year 2020 compared to $31.8 million for the full year 2019. Adjusted EBITDA was higher by $5.4 million in the fourth quarter and full year 2020, primarily related to lower expenses on Livongo devices as a result of the merger. A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”. Financial OutlookTeladoc Health provides guidance based on current market conditions and expectations. Given the uncertainty of the expected path of the COVID-19 pandemic as well as the broader economic impact, our updated guidance is based on what we know today. As this is an evolving situation, circumstances are likely to change, but we believe our guidance ranges provide a reasonable baseline for 2021 financial performance. For the first-quarter 2021, we expect: Total revenue to be in the range of $445 million to $455 million.EBITDA to be in the range of $(46) million to $(43) million.Adjusted EBITDA to be in the range of $45 million to $48 million, including an estimated $7 million in lower expenses primarily related to Livongo devices as a result of the merger.Total U.S. paid membership to be in the range of 51 million to 52 million members and visit fee only access to be available to 22 to 23 million individuals, including 2 to 3 million individuals on a temporary basis.Total visits to be between 2.9 million and 3.1 million. For the full-year 2021, we expect: Total revenue to be in the range of $1.95 billion to $2.0 billion.EBITDA to be in the range of $(110) million to $(90) million.Adjusted EBITDA to be in the range of $255 million to $275 million, including an estimated $20 million in lower expenses primarily related to Livongo devices as a result of the merger.Total U.S. paid membership to be in the range of 52 million to 54 million members and visit fee only access to be available to 22 to 23 million individuals, including 2 to 3 million individuals on a temporary basis.Total visits to be between 12 million to 13 million. Quarterly Conference Call The fourth quarter and full year 2020 earnings conference call and webcast will be held Wednesday, February 24, 2021 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-833-968-2101 for U.S. participants, or 1-236-714-2089 for international participants, and referencing Conference ID Number: 1127504; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link, and will remain available for approximately 90 days. About Teladoc Health Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Ranked best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; and (v) changes to our abilities to recruit and retain qualified providers into our network; and (vi) the impact of the COVID-19 pandemic on our operations, demand for our services and general economic conditions, as well as orders, directives and legislative action by local, state, federal and foreign governments in response to the spread of COVID-19. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share data, unaudited) December 31, December 31, 2020 2019 Assets Current assets: Cash and cash equivalents $733,324 $514,353 Short-term investments 53,245 2,711 Accounts receivable, net of allowance of $6,412 and $3,787, respectively 169,281 56,948 Inventories 56,498 0 Prepaid expenses and other current assets 47,259 13,990 Total current assets 1,059,607 588,002 Property and equipment, net 28,551 10,296 Goodwill 14,581,255 746,079 Intangible assets, net 2,020,864 225,453 Operating lease - right-of-use assets 46,647 26,452 Other assets 18,357 6,545 Total assets $17,755,281 $1,602,827 Liabilities and stockholders’ equity Current liabilities: Accounts payable $46,030 $9,075 Accrued expenses and other current liabilities 83,657 34,440 Accrued compensation 94,593 34,201 Deferred revenue-current 52,356 12,465 Advances from financing companies 13,453 0 Current portion of long-term debt 42,560 0 Total current liabilities 332,649 90,181 Other liabilities 1,616 9,239 Operating lease liabilities, net of current portion 43,142 24,994 Deferred revenue, net of current portion 2,449 2,300 Advances from financing companies, net of current portion 9,926 0 Deferred taxes 102,103 21,678 Convertible senior notes, net 1,379,592 440,410 Commitments and contingencies Stockholders’ equity: Common stock, $0.001 par value; 300,000,000 shares and 150,000,000 shares authorized as of December 31, 2020 and December 31, 2019, respectively; 150,281,099 shares and 72,761,941 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively 150 73 Additional paid-in capital 16,857,797 1,538,716 Accumulated deficit (992,661) (507,525)Accumulated other comprehensive loss 18,518 (17,239)Total stockholders’ equity 15,883,804 1,014,025 Total liabilities and stockholders’ equity $17,755,281 $1,602,827 CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data, unaudited) Quarter Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Revenue $383,321 $156,489 $1,093,962 $553,307 Expenses: Cost of revenue (exclusive of depreciation and amortization, which is shown separately below) 122,942 55,355 390,829 184,465 Operating expenses: Advertising and marketing 93,751 25,356 226,146 109,697 Sales 93,942 16,751 154,052 64,915 Technology and development 92,697 16,246 164,941 64,644 Legal and regulatory 2,610 1,523 8,876 6,762 Acquisition and integration related costs 57,550 2,477 88,236 6,620 General and administrative 341,375 44,482 497,808 157,694 Depreciation and amortization 36,960 9,887 69,495 38,952 Total expenses 841,827 172,077 1,600,383 633,749 Loss from operations (458,506) (15,588) (506,421) (80,442)Loss on extinguishment of debt 99 0 9,077 0 Interest expense, net 20,819 7,581 60,495 29,013 Net loss before taxes (479,424) (23,169) (575,993) (109,455)Income tax benefit (85,457) (4,125) (90,857) (10,591)Net loss $(393,967) $(19,044) $(485,136) $(98,864) Net loss per share, basic and diluted $(3.07) $(0.26) $(5.36) $(1.38) Weighted-average shares used to compute basic and diluted net loss per share 128,298,005 72,564,855 90,509,229 71,844,535 CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands, unaudited) Year Ended December 31, 2020 2019 Cash flows (used in) provided by operating activities: Net loss $(485,136) $(98,864)Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Depreciation and amortization 69,495 38,952 Depreciation of rental equipment 1,697 0 Amortization of right-of-use assets 6,895 6,000 Allowance for doubtful accounts 5,284 2,665 Stock-based compensation 475,531 66,702 Deferred income taxes (90,158) (10,868)Accretion of interest 45,296 25,438 Loss on extinguishment of debt 9,077 0 Change in fair value of contingent consideration (1,009) 1,248 Changes in operating assets and liabilities: Accounts receivable (21,091) (15,884)Prepaid expenses and other current assets (12,565) (2,685)Inventory (24,732) 0 Other assets (8,135) (105)Accounts payable (87,995) 905 Accrued expenses and other current liabilities 20,125 10,026 Accrued compensation 34,819 4,546 Deferred Revenue 17,751 4,815 Operating lease liabilities (6,300) (2,417)Other liabilities (2,360) (605)Net cash (used in) provided by operating activities (53,511) 29,869 Cash flows (used in) provided by investing activities: Capital expenditures (4,024) (3,510)Capitalized software development costs (22,018) (7,390)Proceeds from marketable securities 2,496 52,100 Investment in securities 0 (5,000)Acquisitions of business, net of cash acquired (567,429) (11,187)Net cash (used in) provided by investing activities (590,975) 25,013 Cash flows provided by financing activities: Net proceeds from the exercise of stock options 54,314 33,283 Proceeds from issuance of 2027 Notes 1,000,000 0 Payment of issuance costs of 2027 Notes (24,070) 0 Repurchase of 2022 Notes (228,153) 0 Proceeds from the sale of capped call related to the Livongo Notes 91,659 0 Proceeds from advances from financing companies 6,002 0 Payment from customers against advances from financing companies (8,635) 0 Payment of assumed indebtedness (10,000) 0 Proceeds from employee stock purchase plan 4,722 3,380 Cash paid for withholding taxes on stock-based compensation, net (26,703) (1,569)Net cash provided by financing activities 859,136 35,094 Net increase in cash and cash equivalents 214,650 89,976 Foreign exchange difference 4,321 388 Cash and cash equivalents at beginning of the period 514,353 423,989 Cash and cash equivalents at end of the period $733,324 $514,353 Income taxes paid $1,324 $1,310 Interest paid $14,890 $12,224 Non-GAAP Financial Measures: To supplement our financial information presented in accordance with GAAP, we use adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA, which are non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as the primary measure of our performance. Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which is shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue. We believe that these measures provide investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis. EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, depreciation, amortization and loss on extinguishment of debt. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis. For presentation purposes, foreign exchange gain or loss is included in interest expense, net in our consolidated statement of operations. Adjusted EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, depreciation, amortization, stock-based compensation, loss on extinguishment of debt and acquisition and integration related costs. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis. We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA may vary from that of others in our industry. None of adjusted gross profit, adjusted gross margin, EBITDA nor adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with GAAP as measures of performance. Adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are: Adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;Adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;EBITDA and adjusted EBITDA do not reflect the significant interest expense on our debt;EBITDA and adjusted EBITDA eliminate the impact of income taxes on our results of operations;EBITDA and Adjusted EBITDA do not reflect the loss on extinguishment of debt;Adjusted EBITDA does not reflect the significant acquisition and integration related costs related to mergers and acquisitions;Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; andother companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA differently than we do, limiting the usefulness of adjusted these measures as comparative measures. In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements. We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share and other performance measures. In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. We have not reconciled EBITDA or adjusted EBITDA guidance to GAAP net income (loss) because we do not provide guidance on GAAP net income (loss) or the reconciling items between EBITDA and adjusted EBITDA and GAAP net income (loss) as a result of the uncertainty regarding, and the potential variability of, certain of these items, the effect of which may be significant. Accordingly, a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure is not available without unreasonable effort. The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively: Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin(In thousands, unaudited) Quarter Ended Year Ended December 31, December 31, 2020 2019 2020 2019 Revenue $383,321 $156,489 $1,093,962 $553,307 Cost of revenue (exclusive of depreciation and amortization, which is shown separately below) (122,942) (55,355) (390,829) (184,465) Depreciation and amortization of intangible assets (2,846) (1,301) (12,394) (4,580) Gross Profit 257,533 99,833 690,739 364,262 Depreciation and amortization of intangible assets 2,846 1,301 12,394 4,580 Adjusted gross profit $260,379 $101,134 $703,133 $368,842 Gross margin 67.2 % 63.8 % 63.1 % 65.8 %Adjusted gross margin 67.9 % 64.6 % 64.3 % 66.7 % The following is a reconciliation of Net Loss, the most directly comparable GAAP financial measure, to EBITDA and Adjusted EBITDA: Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA(In thousands, unaudited) Quarter Ended Year Ended December 31, December 31, 2020 2019 2020 2019 Net loss $(393,967) $(19,044) $(485,136) $(98,864) Add: Loss on extinguishment of debt 99 0 9,077 0 Interest expense, net 20,819 7,581 60,495 29,013 Income tax benefit (85,457) (4,125) (90,857) (10,591) Depreciation expense 1,783 682 4,766 3,382 Amortization expense 35,177 9,205 64,729 35,570 EBITDA (421,546) (5,701) (436,926) (41,490) Stock-based compensation 414,380 18,457 475,531 66,702 Acquisition and integration related costs 57,550 2,477 88,236 6,620 Adjusted EBITDA $50,384 $15,233 $126,841 $31,832 Investors:Patrick Feeley914-265-7925pfeeley@teladochealth.com Media:Chris Stenrud860-491-8821pr@teladochealth.com

    View More →
  • Teladoc Health, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 24, 2021 / Teladoc Health, Inc. (NYSE:TDOC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 4:30 PM Eastern Time.

    View More →
  • Teladoc Lower After Posting Wider-Than-Expected Loss

    Teladoc's shares fell after the telemedicine provider posted a wider-than-expected fourth-quarter loss.

    View More →
  • The NEXT: 21 to watch in 2021

    Yahoo Finance's 21 most influential entrepreneurs, leaders, and influencers to watch in 2021.

    View More →
  • Why Teladoc Stock Dropped Today

    What happened Shares of Teladoc Health (NYSE: TDOC) fell 4.8% on Tuesday, as investors sold so-called stay-at-home stocks. So what  With new COVID-19 case counts declining, people have begun to look ahead to an eventual end to the coronavirus pandemic.

    View More →
  • These are the stocks helping to tank the high-flying ARK Innovation ETF over the past week

    The Ark Innovation ETF has been a top performer. The Ark Innovation ETF (ARKK) holds 52 stocks of companies selected by Cathie Wood, founder and CEO of ARK Invest, that are involved with innovation in various technology, products or services. The actively managed exchange traded fund was established on Oct. 31, 2014.

    View More →
  • Teladoc Health to Participate in Cowen Healthcare Conference

    PURCHASE, N.Y., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief financial officer, will participate in the Cowen Healthcare Conference on March 2, 2021, at 12:50 p.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations/. About Teladoc HealthTeladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Ranked best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter. Investors:Patrick Feeley914-265-7925pfeeley@teladochealth.com Media:Jake Mazanke630-640-5253pr@teladochealth.com

    View More →
  • Forget Sundial: These Stocks Offer 500% (or Greater) Upside

    Rather, it's an all-out battle between momentum-focused retail investors on Reddit and Robinhood and perceived big-money institutional investors. Beginning with GameStop, retail investors have piled into dozens of heavily short-sold and/or low-priced stocks with the purpose of driving their share prices into the stratosphere. Canadian marijuana stock Sundial, which was primarily targeted by retail investors for its penny-stock share price, is up 482% over the trailing three months, as of this past weekend.

    View More →